Trial Profile
An Open-Label, Multicenter Study to Evaluate the Pharmacokinetics, Safety, and Efficacy of Ombitasvir (OBV), Paritaprevir (PTV), Ritonavir (RTV) With or Without Dasabuvir (DSV) and With or Without Ribavirin (RBV) in Pediatric Subjects With Genotype 1 or 4 Chronic Hepatitis C Virus (HCV) Infection (ZIRCON)
Status:
Completed
Phase of Trial:
Phase II/III
Latest Information Update: 12 Dec 2022
Price :
$35
*
At a glance
- Drugs Dasabuvir (Primary) ; Ombitasvir/paritaprevir/ritonavir (Primary) ; Ribavirin (Primary)
- Indications Hepatitis C
- Focus Pharmacokinetics; Registrational; Therapeutic Use
- Acronyms ZIRCON
- Sponsors AbbVie; AbbVie Germany
- 22 Dec 2020 Status changed from active, no longer recruiting to completed.
- 25 May 2020 Results (n=26) of efficacy and safety of pediatric-friendly formulations of DAAs in children 3-11years of age enrolled in the study in USA published in the Advances in Therapy
- 09 Oct 2019 This trial has been completed in Germany, according to European Clinical Trials Database.